Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the ...

Vegan diets may enhance performance in semi-professional soccer players, but attention to protein and nutrient intake is crucial for muscle preservation.

Exercise may reduce VF progression among older adults, but vitamin D3 and omega-3 supplementation do not appear to impact rates of new or total VF.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Topline results expected in the third quarter of 2025.SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ...

Costa Rica: A recent systematic review published in the Cureus Journal of Medical Science has shed light on the potential of ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety ...

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder MUNICH, Germany and SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- HMNC ...

CAMBRIDGE, MA, USA I July 21, 2025 I Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on ...